{
    "organizations": [],
    "uuid": "b54651690b2684737b964fca94ca133d7f64d6bc",
    "author": "",
    "url": "https://www.reuters.com/article/brief-fda-acceptance-of-medicines360s-fi/brief-fda-acceptance-of-medicines360s-filing-for-supplemental-nda-for-liletta-52-mg-idUSASB0C705",
    "ord_in_thread": 0,
    "title": "BRIEF-FDA Acceptance Of Medicines360's Filing For Supplemental NDA For Liletta 52 Mg",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "February 22, 2018 / 1:11 PM / Updated 3 minutes ago BRIEF-FDA Acceptance Of Medicines360's Filing For Supplemental NDA For Liletta 52 Mg Reuters Staff 1 Min Read Feb 22 (Reuters) - Allergan Plc: * FDA ACCEPTANCE OF MEDICINES360‘S FILING FOR SUPPLEMENTAL NEW DRUG APPLICATION FOR LILETTA® (LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM) 52 MG Source text for Eikon: Further company coverage:",
    "published": "2018-02-22T15:11:00.000+02:00",
    "crawled": "2018-02-22T15:18:19.015+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "february",
        "pm",
        "updated",
        "minute",
        "ago",
        "acceptance",
        "medicines360",
        "filing",
        "supplemental",
        "nda",
        "liletta",
        "mg",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "allergan",
        "plc",
        "fda",
        "acceptance",
        "medicines360",
        "filing",
        "supplemental",
        "new",
        "drug",
        "application",
        "intrauterine",
        "system",
        "mg",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}